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Abstract Chronic renal failure in children results in im-
paired body growth. This effect is so severe in some
children that not only does it have a negative impact on
their self-image, but it also affects their ability to carry
out normal day-to-day functions. Yet the mechanism by
which chronic renal failure causes short stature is not
well understood. Growth hormone (GH) therapy increas-
es body height in prepubertal children, suggesting that a
better understanding of how GH promotes body growth
may lead to better insight into the impaired body growth
in chronic renal failure and therefore better therapies.
This review discusses what is currently known about
how GH acts at a cellular level. The review discusses
how GH is known to bind to a membrane-bound receptor
and activate a cytoplasmic tyrosine kinase called Janus
kinase (JAK) 2. The activated JAK2 in turn phospho-
rylates tyrosines within itself and the associated GH re-
ceptor, forming high-affinity binding sites for a variety
of signaling molecules. Examples of such signaling mol-
ecules include signal transducers and activators of tran-
scription (Stats), which regulate the expression of a vari-
ety of GH-dependent genes, and the adapter protein Shc,
which leads to activation of the Ras-Raf-MEK-MAP ki-
nase pathway. In response to GH, JAK2 is also known to
phosphorylate the insulin receptor substrates, leading to
activation of phosphatidyl inositol 3’ kinase and most
likely other molecules that have been implicated in the
regulation of metabolism. Finally, the ability of JAK2 to
bind and activate the presumed adapter protein SH2-B is
discussed. SH2-B has been shown to be a potent activa-
tor of GH-promoted JAK2 activity and downstream sig-
naling events. Presumably these and other pathways ini-
tiated by GH combine to result in its ability to regulate
body growth and metabolism.
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Introduction
As early as 1973 [1], growth hormone (GH) was recog-
nized as binding to a membrane-bound receptor. Yet the
mechanism by which GH binding to its receptor elicits
the diverse responses to GH remained elusive for several
more decades. Even cloning of the GH receptor [2] in
1987 did not shed light on the mechanism by which the
GH receptor functioned, because the deduced amino acid
sequence of the cloned rabbit and human liver GH recep-
tors bore no homology to proteins with known function.
Based upon our findings that GH stimulates tyrosyl
phosphorylation of cellular proteins [3, 4] and GH-GH
receptor co-purifies with a tyrosine kinase [5], we hy-
pothesized that GH might act like a number of other
growth factors, i.e., to activate a tyrosine kinase that is
either intrinsic to the receptor or tightly associated with
the receptor. After a prolonged search for our hypothe-
sized GH receptor-associated tyrosine kinase, we identi-
fied Janus kinase 2 (JAK2) as a tyrosine kinase that
binds to activated GH receptor. GH was found to pro-
mote the association of JAK2 with GH receptor, activate
JAK2 and stimulate the phosphorylation of tyrosines
within both the GH receptor and JAK2 [6]. These obser-
vations suggested the following mechanism by which
GH binding to its receptor could initiate a variety of cel-
lular responses (Fig. 1): binding of GH to the GH recep-
tor increases the affinity of JAK2 for GH receptor and
activates JAK2. JAK2 phosphorylates tyrosines within
itself and the associated GH receptor. The phosphorylat-
ed tyrosines within JAK2 and GH receptor form high-af-
finity binding sites for a variety of signaling proteins
containing Src homology (SH) 2 and other phosphotyro-
sine-binding domains. Recruitment of these signaling
molecules to GH receptor/JAK2 complexes initiates a
variety of signaling pathways that lead to the regulation
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of transcription of specific genes, cellular metabolic en-
zymes, and the actin cytoskeleton, ultimately leading to
GH stimulation of body growth and changes in protein,
carbohydrate and fat metabolism. This review identifies
a number of such signaling molecules that are recruited
into GH-signaling pathways as a consequence of JAK2
activation by GH and discusses what is known about
how those signaling pathways mediate the diverse re-
sponses to GH.
The GH receptor is a member of the family
of cytokine receptors, all of which are known
to activate members of the JAK family 
of tyrosine kinases
The GH receptor was the first receptor cloned of what is
now known as the cytokine family of receptors. This
family includes receptors for the hormones growth hor-
mone, prolactin and leptin. It also includes the receptors
for most of the interleukins (ILs) (ILs 2–7, 9–13), inter-
ferons α/β and γ, erythropoietin, thrombopoietin, granu-
locyte colony-stimulating factor, oncostatin M, leukemia
inhibitory factor, ciliary neurotrophic factor, granulocyte
macrophage colony-stimulating factor, and cardiotropin
(reviewed in [7]). Receptors in the cytokine receptor
family were originally classified as a family based upon
limited homology in the extracellular domain, including
two pairs of cysteines and a WSXWS motif [8]. Eventu-
ally, it was recognized that members of this family also
share some homology in the cytoplasmic domain, in par-
ticular, one or two proline-rich motifs [9, 10, 11]. At the
time that our laboratory identified GH and prolactin re-
ceptors as binding to JAK2 [6, 12], Ihle and colleagues
identified JAK2 as a signaling molecule for the receptors
for erythropoietin and IL-3 [13, 14]. It is now known
that all members of the cytokine family of receptors acti-
vate one or more members of the JAK family of tyrosine
kinases, a family that presently consists of JAK1, JAK2,
JAK3 and Tyk2 [7]. The recognition that all members of
the cytokine family bind to and activate members of the
JAK family of tyrosine kinases suggested that some of
the signaling pathways utilized by the non-hormone re-
ceptors in the cytokine family may also be used by the
GH receptor.
GH activates multiple members 
of the signal transducers and activators 
of the transcription (Stats) family
The pathway that immediately drew our attention was
one that had been identified for the IFNs (interferons)
and involves what are now referred to as signal transduc-
ers and activators of transcription (Stats). Presently, sev-
en Stat proteins have been cloned: Stats 1, 2, 3, 4, 5a, 5b
and 6. All Stats contain an SH2 domain. In response to
ligand stimulation, they are recruited to phosphorylated
tyrosines within hormone receptor/JAK complexes and
are phosphorylated themselves on tyrosines. All of them
homo- or heterodimerize, move to the nucleus, bind spe-
cific sequences of DNA and regulate the transcription of
ligand-specific genes [15]. Our laboratory and others in-
vestigated the ability of GH to utilize Stat proteins to
regulate gene transcription. As illustrated in Fig. 2, GH
was found to stimulate the tyrosyl phosphorylation of
Stats 1, 3 and 5. It did not stimulate the tyrosyl phos-
phorylation of Stat2 (data not shown). Consistent with
these Stats serving as signaling molecules for GH, GH
also stimulated their binding to Stat-specific sequences
of DNA [16–20]. These results, and others investigating
the ability of GH to regulate the expression of Stat-spe-
cific reporter gene constructs [21, 22], provide strong ev-
idence that GH regulates gene transcription at least in
part by recruiting and activating Stats 1, 3, 5a, and 5b
(reviewed in [7]).
Figure 2 also illustrates the interesting and important
observation that different ligands are more effective than
Fig. 1 Possible signaling
pathways initiated by binding
of growth hormone (GH) (GHR
GH receptor, P phosphorylated
tyrosines, JAK Janus kinase,
IRS insulin receptor substrate
P13K phosphatidylinositol-3-
kinase, PLC, phospholipase C,
DAG diacylglycerol, 
PKC protein kinase C, 
MAPK mitogen-activated
protein kinase, STAT signal
transducer and activator of
transcription) [Adapted with
permission from Carter-Su C,
Smit LS (1998) Recent Prog
Horm Res 53:61–83]
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others in activating specific Stat proteins, even in a sin-
gle cell type. Thus, in 3T3-F442A cells, GH is better
than IFNγ or leukemic inhibitory factor (LIF) at stimu-
lating tyrosyl phosphorylation of Stat5, whereas IFN-γ is
the most effective at stimulating tyrosyl phosphorylation
of Stat1 and LIF is the most effective of the three ligands
at stimulating tyrosyl phosphorylation of Stat3. Differ-
ences in the level of JAK activation cannot explain this
ligand preference for specific Stats. In 3T3-F442A cells,
GH is more than an order of magnitude better than LIF
or IFNγ at activating JAK2 (judged by JAK2 tyrosyl
phosphorylation), and JAK1 is activated to a similar ex-
tent by all three ligands [18]. It is currently thought that
ligand specificity of Stat activation is due largely to the
presence of high-affinity binding sites for specific Stat
proteins in the receptor. Thus, Stat3 has been shown to
bind with high affinity to the motif pYXXQ [23]; the re-
ceptor for LIF contains seven such motifs, whereas the
receptors for IFNγ and GH contain no such motifs. Simi-
larly, the receptor subunit for IFNγ contains a high-affin-
ity binding site for Stat1 [24] that is absent from the re-
ceptors for LIF and GH. Based upon these observations,
we and others hypothesized that the receptor for GH may
contain multiple high-affinity binding sites for Stats 5a
and 5b. Subsequent studies suggest that GH receptors do
contain multiple binding sites for Stat5a and 5b [25, 26],
explaining at least in part why GH is such a potent acti-
vator of Stat5a and 5b. In terms of their physiological
role in GH action, Stats 1 and 3 have been implicated in
the regulation of c-fos gene expression by GH [16, 17,
22, 27], whereas Stats 5a and 5b have been shown to
bind to gamma-activated sequence (GAS)-like sequences
in the promoters of the genes encoding serine protease
inhibitor 2.1, insulin, the acid labile subunit (ALS) of
Fig. 2 GH, leukemia-inhibitoy factor (LIF), and interferon-γ (IFNγ)
induce tyrosyl phosphorylation of Stat1, Stat3 and Stat5 in 3T3-
F442A fibroblasts. 3T3-F442A fibroblasts were incubated for 
15 min in the absence of hormone or with 500 ng/ml human GH,
25 ng/ml human LIF or 10 ng/ml murine IFNγ. Whole cell lysates
were immunoprecipitated with antibodies to Stat1 (αStat1), Stat3
(αStat3) or Stat5 (αStat5), as indicated. Immunoprecipitated pro-
teins were subjected to Western blot analysis using anti-phospho-
tyrosine antibody. Migrations of Stat1, Stat3 and Stat5 are indi-
cated [Reprinted with permission from Carter-Su C, King APJ,
Smit LS, VanderKuur JA, Argetsinger LS, Campbell GS, Huo W
(1997) J Anim Sci 75 [Suppl 2]:1–10]
Fig. 3 GHR signaling via
signal transducers and





Spi serine protease inhibitor,
ALS acid labile subunit)
(Adapted with permission from
[7]) 
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IGF-binding proteins, and a number of male-specific cy-
tochrome P450 enzymes (Fig. 3) [21, 25, 28–30]. Studies
using mice lacking Stat5a, Stat5b or both have also im-
plicated Stat5a and/or Stat5b in the regulation of some of
these genes and in the growth-promoting actions of GH
[31–33].
While the phosphorylation, dimerization and DNA-
binding properties of Stats have been well studied, little
is known about how Stat proteins move from cytokine
receptor-JAK complexes, presumably at the plasma
membrane, to the nucleus. Our laboratory has started to
investigate this process by using green fluorescent pro-
tein (GFP)-tagged Stat5b [34]. When expressed in mon-
key kidney derived COS-7 cells, murine NIH-3T3 fibro-
blasts or human fibrosarcoma 2C4 cells, GFP-tagged
Stat5b was observed to be distributed within the cyto-
plasm and the nucleus, as revealed by laser scanning
confocal microscopy of live cells. GH stimulation caused
the GFP-Stat5b to accumulate in the nucleus of all three
cell types within 30 min. When alanine substitutions
were introduced into several regions of Stat5b and GH-
dependent nuclear localization was assessed, only the
mutation that prevented binding to DNA (466VVVI469)
abrogated GH-stimulated nuclear localization. This mu-
tant fusion protein is tyrosyl phosphorylated and dimer-
izes in response to GH. These results suggest that either
high-affinity binding to DNA contributes to nuclear ac-
cumulation of Stat5b or that amino acid residues
466–469 are crucial for two functions, accumulation of
Stat5b into the nucleus and DNA binding.
GH stimulates the Ras-MAP kinase and insulin
receptor substrate-phosphatidylinositol 3’ kinase
pathways
GH binding to GH receptors initiates a variety of path-
ways in addition to pathways involving Stat proteins.
Two of these include the Ras-MAP kinase pathway and
the pathway involving the insulin receptor substrate (IRS)
proteins (Fig. 1). We have shown that GH binding to its
receptor recruits the SH2 domain containing adapter pro-
tein Shc, to GHR-JAK2 complexes, at least in part via the
SH2 domain of Shc (Fig. 4). Shc becomes phosphorylat-
ed on tyrosines, presumably by the GH receptor-associat-
ed JAK2. The phosphorylated Shc then binds grb2-SOS
complexes, presumably via the SH2 domain of grb2. This
results in the activation of the small GTP-binding protein
Ras, which results in the activation of the serine/threo-
nine kinase Raf, which activates the mixed function tyro-
sine/serine/threonine kinase MEK, which activates the
extracellular signal regulated kinases ERKs 1 and 2 [35,
36]. Whereas MEK appears to be quite specific for ERKs
1 and 2, ERKs themselves are thought to phosphorylate
many different proteins, including cytoskeletal targets
(e.g., MAPs 1, 2, 4, Tau and caldesomon), cytosolic pro-
teins (e.g., p90rsk, cytoplasmic phospholipase A2, phos-
pholipase (γ) and nuclear proteins, including Elk-1, c-fos,
c-Jun, ATF-2, c-myc and p53 [37, 38]. Of these potential
substrates, GH has been shown to stimulate the phospho-
rylation of p90rsk [39], phospholipase A2 [40], and Elk-1
[41], suggesting that GH regulation of at least some of
these proteins is mediated by this MAP kinase pathway.
Interestingly, the c-fos gene, which is regulated by GH,
contains both a Sis-inducible element, which is known to
bind Stats 1 and 3, and a serum response element (SRE),
which binds SRF and ternary factor, such as Elk-1. Both
the Sis-inducible element (SIE) and SRE have been
shown to be required for maximal activation of the c-fos
promoter [42], suggesting that the different pathways ini-
tiated by GH may act in concert to regulate specific cellu-
lar functions, such as c-fos gene expression.
Insulin receptor substrates represent another pathway
by which GH may elicit some of its cellular effects
(Fig. 5). We and others have now shown that GH stimu-
lates the tyrosyl phosphorylation of IRS1 and IRS2, pre-
sumably by JAK2 although the exact mechanism by
Fig. 4 GHR signaling via the Ras-MAP Kinase pathway. Solid
arrows and signaling molecules and bold targets indicate path-
ways and proteins regulated by GH. Dotted arrows and targets in
medium type indicate pathways and targets utilized in cells treated
with other cytokines and growth factors that activate MAP kinase
or are detected in vitro. These have not yet been shown to be
involved in GH signal transduction (PLA2 phospholipase A2, TCF
ternary complex factor, GTP guanosine triphosphate, Sos son of
sevenless, MEK MAP kinase/ERK kinase, TAL T-cell acute lym-
phoblastic leukemia gene, NF nuclear factor IL-6, ATF activating
transcription factor-2, MAPKAP MAP kinase activated protein
kinase-2) (Reprinted with permission from [7])
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which this occurs is unknown. The phosphorylated IRS
proteins have been shown to recruit both the p85 regula-
tory subunit of phosphatidylinositol 3 (PI 3’) kinase and
the SH2-domain containing tyrosine phosphatase SHP2
[43–46]. Binding of both of these proteins to phosphory-
lated tyrosines within IRS proteins has been shown to
activate their enzymatic activity [47–49]. Based upon
what is known about the actions of PI 3-kinase and the
actions of GH, pathways that may lie downstream of IRS
and PI 3-kinase proteins include the following: (1) the
rapid and transient stimulation of glucose transport and
lipid synthesis seen in adipocytes following a period of
GH deprivation; (2) regulation of MAP kinase activity
and the downstream regulation of c-fos gene expression;
(3) regulation of certain isoforms of protein kinase C;
and (4) the regulation of p70rsk and the regulation of
cell cycle progression [7].
GH stimulates the binding of SH2-Bβ to JAK2
and the tyrosyl phosphorylation of SH2-Bβ
In addition to the pathways just described, other labora-
tories have provided evidence for the activation of phos-
pholipase C, increased diacylglycerol, increased activity
of certain isoforms of PKC, and regulation of L-type cal-
cium channels [7] (Fig. 1). Whether or not these respons-
es to GH are dependent upon JAK2 is not yet known, al-
though in at least one cell type the ability of GH to stim-
ulate L-type calcium channels appears to be independent
of JAK2 activation [50]. All of the signaling pathways
just described were identified because they involve sig-
naling molecules activated by other tyrosine kinases. In
an effort to identify signaling molecules unique to GH or
to JAK2-coupled receptors, we decided to pursue strate-
gies that would identify new signaling molecules. To this
end, we used the yeast two-hybrid system to try to iden-
tify signaling molecules that bound to activated JAK2. A
truncated form of JAK2 containing the kinase domain
was fused to the DNA-binding portion of Lex A and
used as the bait to screen a rat fat tissue-derived cDNA
library. By this technique, we identified an SH2 domain
containing fragment of SH2-Bβ (SH2-Bβc) (Fig. 6) as a
binding partner of activated, but not kinase-inactive,
JAK2 [51]. SH2-B has the properties of an adapter or
scaffolding protein (Fig. 6), in that it contains a number
of potential protein-protein interaction domains and no
homology to proteins with other known functions. Thus,
it contains an SH2 and PH domain, multiple proline-rich
domains, and multiple serines/threonines and tyrosines,
which if phosphorylated could form binding sites for ad-
ditional signaling proteins. We carried out multiple as-
says to verify that SH2-B and JAK2 form a complex
[51]. Firstly, we showed in a yeast two-hybrid system
that SH2-Bβ binds to constitutively activated and tyro-
syl-phosphorylated wild-type JAK2 but not to unphos-
Fig. 5 GHR signaling via in-
sulin receptor substrate-1 
(IRS-1) and IRS-2. Solid mole-
cules and arrows indicate signa-
ling molecules and pathways
regulated by GH. Dashed mole-
cules and arrows indicate signa-
ling proteins known to bind 
IRS-1 and/or IRS-2 via SH2 do-
main-mediated interactions (Nck, 
Grb-2, fyn) in response to in-
sulin, proteins with enzymatic
activities that are stimulated by
the action of phosphatidylino-
sitol-3’-kinase (P13K), or signa-
ling pathways utilized in cells
treated with insulin. These have
not yet been shown to be involv-
ed in GH signal transduction
(SHP2 SH2 domain containing
tyrosine phosphatase) (Reprinted
with permission from [7])
Fig. 6 Schematic represen-
tation of SH2-B isoforms,
truncations and mutations. The
PH and SH2 domains, proline-
rich regions (PP), and all
tyrosines (Y) are noted
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phorylated, inactive JAK2 K882E in which the critical
lysine in the kinase domain is replaced with a glutamine.
Secondly, we showed that when SH2-Bβ and JAK2 are
coexpressed in COS cells, SH2-Bβ and JAK2 form a
complex that can be precipitated with antibody to SH2-
Bβ (αSH2-Bβ). The SH2-Bβ that is coexpressed with
wild-type but not kinase-dead JAK2 is tyrosyl phosphor-
ylated. Thirdly, activated and tyrosyl-phosphorylated
JAK2 from GH-treated 3T3-F442A cells binds to SH2-
Bβ expressed as a glutathione-S-transferase fusion pro-
tein to a much greater extent than inactive, untyrosyl-
phosphorylated JAK2 from control cells. The SH2 do-
main of SH2-B is sufficient for this interaction. Finally,
αSH2-Bβ immunoprecipitates JAK2 from GH-treated
3T3-F442A fibroblasts to a much greater extent than
from control 3T3-F442A cells (Fig. 7). GH also pro-
motes the tyrosyl phosphorylation of SH2-B, suggesting
that SH2-B not only binds to JAK2 in response to GH,
but also is tyrosyl phosphorylated by the activated JAK2.
Interestingly, when the αSH2-Bβ immunoprecipitate is
immunoblotted with αSH2-Bβ, multiple bands migrating
with a molecular weight appropriate for SH2-Bβ are vis-
ible, both in the presence and absence of GH. Based up-
on studies using the serine/threonine-specific phospha-
tase protein phosphatase 2A (PP2A), the multiple bands
are believed to represent SH2-Bβ that is phosphorylated
on serines/threonines to different extents. Taken together,
these results suggest that, in response to GH, JAK2 is re-
cruited to the GH receptor, is activated and autophospho-
rylates thereby forming one or more binding sites for the
SH2 domain of SH2-Bβ. Upon binding to JAK2, SH2-
Bβ itself becomes phosphorylated on tyrosines, resulting
in additional binding sites for signaling molecules.
SH2-Bβ is a potent activator of JAK2 activity
Because SH2-Bβ binds directly to JAK2, we examined
whether SH2-B might regulate the activity of JAK2. To
facilitate these experiments, we introduced a point muta-
tion in the SH2 domain of SH2-Bβ [SH2-Bβ (R555E)],
which is known to prevent binding of SH2 domains to
phosphorylated tyrosines (Fig. 6). This mutated SH2-Bβ
(R555E) would be expected to show greatly diminished
binding to JAK2. We coexpressed wild-type SH2-Bβ
and SH2-Bβ (R555E) with JAK2 in COS-7 cells, pre-
pared cell lysates, and blotted the lysates with antibody
to phosphotyrosine. Figure 8 illustrates that cells overex-
pressing wild-type SH2-Bβ exhibit greatly enhanced lev-
els of tyrosyl-phosphorylated proteins including JAK2.
In contrast, tyrosyl phosphorylation of cellular proteins
was not enhanced by SH2-Bβ (R555E). The increased
tyrosyl phosphorylation required the presence of JAK2;
overexpression of SH2-Bβ in the absence of JAK2 did
not result in enhanced phosphorylation of cellular pro-
teins. This result suggests that one function of SH2-Bβ is
to stimulate the activity of JAK2. Subsequent studies
support this initial finding [52]. Thus, overexpression of
SH2-Bβ, but not of SH2-Bβ (R555E), stimulates the ty-
rosyl phosphorylation of JAK2 and the enzymatic activi-
ty of JAK2, the latter assessed by the ability of immuno-
precipitated JAK2 to autophosphorylate in an in vitro as-
say. In addition, when GH receptor and SH2-B are coex-
pressed in COS-7 cells, the presence of SH2-B enhances
Fig. 7 GH-dependent association of SH2-Bβ with tyrosyl-phos-
phorylated JAK2 and tyrosyl phosphorylation of SH2-Bβ. 3T3-
F442A cells were treated for 15 min with 500 ng/ml GH (lanes 2,
4 and 6) or with vehicle (lanes 1, 3, and 5). Whole cell lysates
were immunoprecipitated with αSH2-B and subsequently im-
munoblotted with αPY (lanes 5 and 6). The blot corresponding to
lanes 5 and 6 was stripped and reprobed with αSH2-B (lanes 3
and 4) and then stripped again and reprobed with αJAK2 (lanes 1
and 2). The migration of molecular weight standards (x10–3),
JAK2 and SH2-Bβ is indicated (Reprinted in modified form with
permission form [51])
Fig. 8 The SH2 domain of SH2-Bβ is required for SH2-Bβ-in-
duced tyrosyl phosphorylation of JAK2 and multiple other cellular
proteins. COS cells were cotransfected with plasmid (4 µg) en-
coding JAK2 and either control plasmid (10 µg) or plasmid 
(10 µg) encoding SH2-Bβ (WT) or SH2-Bβ(R555E) (RE). After
48 h, cells were lysed, and proteins in the lysates were resolved by
SDS/PAGE, immunoblotted with αPY (top panel), and reprobed
with αJAK2 (middle panel). In a parallel experiment proteins in
the lysates were immunoblotted with αSH2-B (bottom panel) (Re-
printed in modified form with permission from [52])
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the ability of GH to stimulate the tyrosyl phosphoryla-
tion of endogenous JAK2. Consistent with SH2-B acti-
vating JAK2, overexpression of SH2-B with GH recep-
tor and with Stat3 or Stat5b enhances the ability of GH
to stimulate the tyrosyl phosphorylation of the respective
Stat. Thus, one of the actions of SH2-B in GH signaling
appears to be the enhancement of JAK2 activation by
GH.
Summary and conclusions
All of these results contribute to our current understand-
ing of how GH elicits its diverse responses in a variety
of cell types. To summarize (Fig. 1), GH is thought to
bind to two GH receptors. The resulting change in recep-
tor structure and/or dimerization increases the affinity of
the receptor for JAK2 and activates JAK2. The activated
JAK2 tyrosyl phosphorylates itself as well as the GH re-
ceptor, forming high-affinity binding sites for a number
of signaling proteins. Many of these proteins become
phosphorylated on tyrosines, presumably by JAK2.
These signaling proteins include the: (1) Stat proteins
that are thought to regulate the transcription of a variety
of GH-dependent genes; (2) IRS proteins that recruit 
PI 3-kinase and SHP2 and most likely other proteins,
some of which are believed to regulate cellular metabo-
lism and perhaps the transcription of some GH-depen-
dent genes; (3) Shc proteins, which are thought to be the
first step in the Ras-MAP kinase pathway, which has
been shown to regulate a variety of cellular proteins; and
(4) SH2-Bβ, a protein that activates JAK2 and may link
other more specific signaling pathways to GH recep-
tor/JAK2 complexes. It is remarkable to think that all of
these pathways have been delineated largely within the
past 6 years. Presumably, the next 6 years will reveal ad-
ditional signaling pathways required for the known ac-
tions of GH, including the regulation of insulin-like
growth factor-I, as well as for new actions of GH. Hope-
fully this new information will explain why children suf-
fering from chronic renal failure are short and suggest
therapies to make them grow taller.
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